FDA approves G1 Therapeutics’ Cosela for reducing chemotherapy-induced bone marrow suppression

G1 Therapeutics has achieved a significant milestone with the recent U.S. Food and Drug Administration (FDA) approval of Cosela (trilaciclib), a pioneering treatment designed to ... Read More